Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 121.07 <%= Resources.Global.txtDown %>
Updated 18/05/2018
Change % -0.07% Stock price decreasing
Change -0.08 Stock price decreasing
Volume 404,901
High $ 121.63
Low $ 120.15
Open $ 121.12
ISIN
Prev close $ 121.15
# of shares 222.50M
Market cap 26,938M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  121.07 -1.4% Stock price decreasing 12.3% Stock price increasing 3.4% Stock price increasing 12.0% Stock price increasing 6.4% Stock price increasing
Powered by TradingView

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
21 May 2018 04:09:23
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180515.2 - EUROWEB3 - 2018-05-21 05:09:23 - 2018-05-21 04:09:23 - 1000 - Website: OKAY